

RESEARCH ARTICLE OPEN ACCESS

Inhibition of Autophagy Reveals ATR Protein Kinase as a Key Mediator of Cisplatin Sensitivity in Osteosarcoma

Janice S. Pereira¹ | Gabriel Rosa¹ | Aine Pears¹ | Beata Burczynska¹ | Britta Stordal¹  | Scott J. Roberts² | Helen C. Roberts¹ 

¹Department of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK | ²Department of Comparative Biomedical Sciences, Royal Veterinary College, London, UK

Correspondence: Helen C. Roberts (h.roberts@mdx.ac.uk)

Received: 19 June 2025 | **Revised:** 16 September 2025 | **Accepted:** 9 February 2026

Keywords: ATG7 | ATR | autophagy | chemoresistance | osteosarcoma

ABSTRACT

Introduction: Osteosarcoma (OS) is the most common primary malignant bone tumor. Although the introduction of chemotherapy has improved the survival rate of OS patients, chemoresistance remains a major clinical problem underlying poor survival outcome. This study investigated the role of autophagy in OS chemoresistance and identified ATR as a novel upstream regulator linking DNA damage signaling, autophagy, and chemoresistance.

Results: Elevated levels of autophagy were found in advanced grade and stage OS tumors, and higher autophagy levels were shown to be associated with poorer OS disease outcome. Chemotherapy significantly increased autophagy levels in HOS-143B cells, while autophagy inhibition by autophagy-related gene 7 knockout (*ATG7*^{-/-}) significantly enhanced cisplatin (CIS) sensitivity in HOS-143B cells. A kinase screen revealed a reduction in the phosphorylation of p53 (S15) in *ATG7*^{-/-} HOS-143B cells. ATR phosphorylates p53 at S15 responsible for DNA Damage Response (DDR), and ATR inhibition increased CIS sensitivity of HOS-143B cells via apoptosis. Subsequent analysis verified that ATR inhibition decreased phosphorylation of p53 at S15 and blocked autophagy in CIS-treated HOS-143B cells.

Conclusion: These findings highlight ATR inhibition as a unique therapeutic strategy that simultaneously disrupts DDR signaling and autophagy, thereby enhancing CIS sensitivity. Targeting ATR could reduce the required CIS dosage, limit treatment-associated toxicity, and ultimately improve survival and clinical outcomes for OS patients.

1 | Introduction

Osteosarcoma (OS) is a primary malignant tumor of the bone with a worldwide incidence of 3.4 cases per million per year [1, 2]. It can affect any bone but shows a predilection for bones with rapid growth rate such as the distal femur (43%), the proximal tibia (23%), and the proximal humerus (10%) [3]. The age distribution of OS is bimodal, with the first peak at 10–20 years of age and a second peak at 60–70 years of age. The former peak

suggests a relationship with the expanding growth plates during puberty and the latter peak represents a consequence of Paget's Disease of Bone, dedifferentiated chondrosarcomas and/or prior radiation therapy [4]. Before 1970, surgical resection was the primary treatment for OS. However, the advent of dose-intensive chemotherapy led to a remarkable improvement in prognosis for patients with localized OS (80% of cases) [2]. Today, multi-agent dose-intensive chemotherapy, mainly consisting of cisplatin (CIS), doxorubicin hydrochloride (DOX) and methotrexate is

Abbreviations: *ATG7*, autophagy related 7; ATM, ataxia telangiectasia mutated; ATMi, ATM inhibitor; ATR, ataxia telangiectasia and Rad3-related; ATRi, ATR inhibitor; CIS, cisplatin; DDR, DNA damage response; DOX, doxorubicin hydrochloride; FACS, fluorescence-activated cell sorting; KO, knockout; *MAP1LC3B*, microtubule associated protein 1 light chain 3 beta; NTC, non targeting control; OS, osteosarcoma; RT, room temperature; S15, serine 15; *SQSTM1*, sequestosome 1.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Cancer Medicine* published by John Wiley & Sons Ltd.

the gold standard treatment for OS [5]. Neoadjuvant chemotherapy is initiated 10 weeks before surgery (limb-salvage surgery or amputation) to shrink large tumors. Adjuvant chemotherapy is administered for one year following radical resection to destroy the remaining tumor cells. This multimodal treatment approach has evolved to be the most efficacious way to increase the survival rate of OS patients and has significantly improved the 5-year survival rate of OS patients without metastasis from 20% to almost 70% [2, 6]. However, some patients can resist chemotherapy leading to tumor relapse and metastasis [7].

OS exhibits both intrinsic as well as acquired resistance to chemotherapy. Due to intrinsic resistance, OS is often treated with a higher dose of chemotherapy than other cancers. Despite this, it quickly develops acquired resistance, making OS one of the most resistant cancers to chemotherapy [8, 9]. Accumulated evidence suggests that a cell survival process called autophagy is one of the main mechanisms underlying chemoresistance in several cancers, including OS [10–13]. Studies have reported that autophagy is activated in response to DNA damage-inducing chemotherapy to restore cellular homeostasis and evade cellular death [14]. In this process, damaged cellular organelles, cytoplasmic components as well as misfolded proteins are sequestered by autophagosomes which later fuse with lysosomes for lysosomal degradation. Subsequently, degradation products such as nucleotides, amino acids, fatty acids, sugars and ATP are transported to the cytosol where they are reused by the cell to improve cellular viability, giving rise to the chemoresistant phenotype [9, 15].

The autophagy pathway is regulated by various autophagy-related proteins and studies have been focusing on targeting these protein levels to investigate the prospects for improving survival outcome of cancer patients. A study by Desai et al. [16] showed that the transcriptional expression of *ATG7* is controlled by heat shock factor 1 (*HSF1*) and has an inverse correlation with the chemotherapeutic prognosis of breast cancer patients. Furthermore, knockdown of *HSF1* reduced autophagy induction via *ATG7* inhibition in breast cancer cells treated with chemotherapy and enhanced the breast cancer cells' sensitivity to carboplatin treatment. In esophageal squamous cell carcinoma, *ATG7* interference was shown to increase sensitivity to cisplatin treatment by enhancing apoptotic cell death. These and several other studies suggest that autophagy inhibition via suppression of *ATG7* levels alongside standard of care treatment could enhance the anti-cancer effects and thereby improve patient survival outcome [17, 18].

Emerging studies in other tumor types have implicated upstream kinases and stress response pathways such as the Ataxia Telangiectasia and Rad3-related protein (ATR) in modulating autophagy through phosphorylation of autophagy-related proteins such as BECLIN1, LC3, ATG31, ATG14L and ATG7 [19–21]. ATR is primarily known for its role in the DNA damage response (DDR) in response to replication stress, which is often induced by chemotherapeutic agents. However, the role of ATR in regulating autophagy in OS and, more specifically, in influencing *ATG7*-dependent autophagy and chemoresistance has not yet been elucidated.

The primary aim of this study was to further investigate the role of autophagy and ATR signaling in OS chemoresistance by

knocking out *ATG7* in highly aggressive/metastatic HOS-143B cells. In doing so, the study aimed to uncover novel interactions between the DDR pathway and autophagy, potentially identifying ATR as a key regulator of chemoresistance in OS.

Our study reveals novel therapeutic approaches and proposes combinatory strategies involving inhibition of autophagy and targeting of the ATR pathway to overcome resistance and improve outcomes for OS patients.

2 | Materials and Methods

2.1 | LC3 Immunohistochemistry of OS Tissue Microarray and MAP1LC3B Gene Profile Analysis

A commercially available human OS tissue microarray (AMSBIO, OS804c) was probed for LC3 (A/B subtypes) expression to assess autophagy levels in OS biopsies. Sections were deparaffinized with xylene and rehydrated through graded ethanol. Antigens were retrieved with sodium citrate buffer (95°C–98°C) for 10 min and quenched with 3% hydrogen peroxide before blocking in 5% Normal Goat Serum. LC3 A/B (D11) XP Rabbit mAb (Cell Signaling Technology, 3868) primary antibody was incubated overnight at 4°C. The next day, after washing the slide, the secondary antibody (SignalStain Boost Detection Reagent, Cell Signaling Technology, 8114) was applied for 30 min at RT and stained with SignalStain DAB Substrate Kit (Cell Signaling Technology, 8059P). The nuclear counterstain was carried out using hematoxylin. Images were obtained using Eclipse 50i (Nikon, Tokyo, Japan) and stain intensity was quantified using ImageJ software. For this study, an area fraction method was used to calculate LC3 expression in the OS histological samples. This calculates the area percentage of DAB chromogen signal normalized to the overall area of the biopsy tissue (quantification was performed at 40× magnification). *MAP1LC3B* gene profile analysis from an integrative study of 88 mixed OS tumors (mesenchymal) (GSE42352) was obtained from R2 Genomics Analysis and Visualization platform (<https://hgserver1.amc.nl/cgi-bin/r2/main.cgi>).

2.2 | Cell Lines and Culture

HOS-143B (ATCC, CRL-8303, authenticated) cells were cultured in 1× DMEM + GlutaMAX (ThermoFisher Scientific) supplemented with 10% FBS (ThermoFisher Scientific), 1% non-essential amino acids (ThermoFisher Scientific), 1% sodium pyruvate (ThermoFisher Scientific), and 1% penicillin–streptomycin (ThermoFisher Scientific). In addition, 0.2% 5-bromo-2'-deoxyuridine was added for cell expansion (Sigma). The cells were grown in a humidified chamber with 5% CO₂ at 37°C and were routinely checked for mycoplasma and were mycoplasma-free.

2.3 | Dose Response Assay

1×10⁴ cells/well in 100 μL of cell culture media/well were seeded in a 96 well plate and left to attach overnight. Cells were treated in triplicates with a two-fold serial dilution of

chemotherapy (Doxorubicin or Cisplatin, Sigma-Aldrich) to reach a final volume of 200 μ L/well. After 48 h of incubation, the cells were washed with PBS and incubated with 100 μ L of fresh acid phosphatase substrate (Sigma-Aldrich) in sodium acetate buffer (0.00263 g/mL) for 1.5 h. Subsequently, 50 μ L of 1 M sodium hydroxide (Sigma-Aldrich) was added. Absorbance was measured at 405 nm on a FLUOstar Omega microplate reader. Cell viability graphs (non-linear regression-curve fitting) and bar graphs for the IC₅₀ were plotted using GraphPad Prism (GraphPad Software, CA, USA).

2.4 | Western Blotting for Protein Analysis

20 $\times$ 10⁴ cells were grown for 24 h prior to drug treatment (48 h). Nitrocellulose membranes were incubated with primary antibody for 1 h (1:1000; Cell Signaling Technology, 12741, LC3 A/B; 5114, p62; 8558, ATG7; 12994, ATG5, p53 (7F5), 2527, Phospho-p53 (S15), 9284) at 4°C. Binding of HRP-linked secondary antibody (1:2000; Cell Signaling Technology, 7074) was visualized by enhanced chemiluminescence using Li-Cor Odyssey Fc machine and quantified using Image Studio (Licor, Cambridge, UK). Normalization for total protein was performed by reprobing the membrane with mouse anti-mouse β -actin (1:1000, Mouse IgG; Abcam) for 1 h at RT, followed by goat anti-mouse IgG HRP (1:2000; Biorad) for 1 h at RT.

2.5 | Immunofluorescence for LC3 Punctate

1 $\times$ 10⁴ cells were seeded in 8-well chamber slide (Sigma Aldrich) and left to attach overnight. Cells were treated the following day and incubated for an additional 48 h. Cells were fixed in ice-cold 100% methanol and blocked in 5% Normal Goat Serum for 1 h at RT. LC3 A/B (D11) XP Rabbit mAb (Cell Signaling Technologies) was added and the cells incubated overnight at 4°C before being incubated with Alexa Fluor 488 Conjugate secondary antibody (Cell Signaling Technologies) and mounted in Antifade Mounting Medium with DAPI (Vector Labs). Images were acquired with Confocal Microscopy Leica DMI4000 B (Leica Microsystems).

2.6 | RNP-CRISPR/Cas9 KO of ATG7 in HOS-143B Cells

For specific Knock out (KO) of the *ATG7* gene, Single guide RNAs (sgRNAs) targeting Exon 11 were obtained from the predesigned TrueGuide Synthetic gRNA library (ThermoFisher Scientific, CRISPR1032818_SG); 5'-TTCCAATAGCTGGGCAGCAA-3'. TrueGuide sgRNA Negative Control (ThermoFisher Scientific) 5'-AAAUGUGAGAUCAGAGUAAU-3' was used as a non-targeting control (NTC). The *ATG7* KO cell line was generated by reverse transfecting TrueGuide sgRNA and TrueCut Cas9 Protein v2 (ThermoFisher Scientific) using Lipofectamine CRISPRMAX Cas9 Transfection Reagent (ThermoFisher Scientific) as per manufacturer's protocol. The first step of the transfection involved the preparation of the Cas9 protein/gRNA/Cas9 Plus reagent solution in Opti-MEM I Reduced Serum Medium, called the RNP complex.

Then, 1.5 μ L lipofectamine CRISPRMAX was diluted in 25 μ L Opti-MEM for 1 min, mixed with the RNP complex and incubated for 15 min at RT. Then, 50 μ L of RNP-Lipofectamine mix followed by 8 $\times$ 10⁴ cells/wells were added to each well of a 24-well plate to reach a total volume of 200 μ L/well. Cells were incubated at 37°C for 72 h and then harvested for cleavage detection and downstream analysis. GeneArt Genomic Cleavage Detection Kit (ThermoFisher Scientific) was used for cleavage detection, following the manufacturer's protocol. Single cell clonal isolation was carried out by limiting dilution method. Cells were plated in a full 96-well plate at a seeding density of 8 cells/mL. Clones were selected based on single colony growth and were later expanded into 6 well plates. After obtaining confluency of 50%–70%, protein lysates were retrieved from each clone and were probed for ATG7 expression by western blotting. Clones were selected based on no ATG7 expression and this was confirmed by qRT-PCR (primers: ATG7 F: 5'GGCGGAGGCACCAAATGAT3' R: 5'CCACATCCAAGGCACTGCTA3'; GAPDH: F: 5'AATCCCATCACCATCTTCCA3' R: 5'TGGACTCCACGACGTACTCA3').

2.7 | Wound Healing Migration Assay

To determine the effect of ATG7 KO on migration activity in osteosarcoma, 2 $\times$ 10⁵ cells were seeded in a 6 well plate and allowed to attach overnight. Following treatment with DOX (0.75 μ M) or CIS (5 μ M) for 48 h, the confluent cell monolayer was scratched down the center of each well using a 200 μ L tip. Subsequently, the monolayer was washed with PBS and fresh culture media was replaced in each well. The wounds were assessed under 10 $\times$ objective at 0 and 24 h and photographed. The distance migrated was analyzed from 3 points for each sample [22].

2.8 | Proteome Profiler Human Phospho-Kinase Array

The effect of *ATG7* KO on phospho-kinase signaling pathways was investigated using the Proteome Profiler Human Phospho-Kinase Array (R&D Systems) for simultaneous detection of phosphorylation levels in 43 protein kinases across multiple pathways. In order to isolate proteins, 5 $\times$ 10⁵ cells were seeded in 75 cm² flasks and incubated for 72 h. After incubation, the detection of phosphorylation levels of kinases/related proteins was carried out following the manufacturer's instructions. Membranes were imaged on the Odyssey Fc Imaging system (Licor, Cambridge, UK).

2.9 | Cell Death Analysis Using Flow Cytometry

Cell death analysis was performed using the Annexin V/PI double staining kit (ThermoFisher Scientific). The cells were trypsinised, washed twice with 1 $\times$ PBS, then resuspended in 1 $\times$ binding buffer. The cell suspension (1 $\times$ 10⁵ cells in 100 μ L) was transferred into a FACS tube and stained with 5 μ L of PI and 5 μ L of Annexin V for 15 min at RT. Further, an extra 400 μ L binding buffer was added to each tube prior to analysis using

the BD FACSCalibur (BD Biosciences, NJ, USA) alongside CellQuest Pro software for analysis. A minimum of 10,000 cells were acquired for each sample.

2.10 | Statistical Analysis

All data were expressed as means $\pm$ standard deviation (SD)/standard error of mean (SEM). Error bars in all figures indicate SD/SEM. Statistical significance for the differences between pairs of conditions was analyzed by a two-sample *t*-test. One-way ANOVA was used to compare more than two conditions. The criterion for statistical significance for an experiment that was independently and successfully repeated three or more times was considered as *p*-value less than or equal to 0.05.

3 | Results

3.1 | High Levels of Autophagy Relate to Reduced Survival in High-Grade OS

Immunohistochemical staining of OS core biopsies for LC3 protein levels (A/B subtypes) revealed a clear pattern of autophagy levels corresponding to OS tumorigenesis and progression. The highest LC3 levels were observed in grade 3 OS tumors followed by grade 2 and normal cortical bone tissue, as shown in Figure 1A,B. By further grouping the results based on stage, LC3 was expressed at highest levels in the most advanced tumor subtypes followed by less aggressive subtypes and normal bone (Figure 1A,C). These OS biopsies reflected patients between the age of 13 to 64, with no observed difference in gender and tumor location. Samples categorized as grade 2 and grade 3 were T1N0M0 and T2N0M0 as per the TNM staging system, respectively, indicating no record of nearby lymph node dissemination and metastasis.

MAP1LC3B profile analysis from an integrative study of 88 mixed OS tumors (mesenchymal) (GSE42352) obtained from R2 Genomics Analysis and Visualization platform (<https://hgserver1.amc.nl/cgi-bin/r2/main.cgi>) revealed a strong link between *MAP1LC3B* levels and OS patient prognosis. As shown in Figure 1D, the patient group with significantly higher *MAP1LC3B* gene expression levels ($n = 62$) was associated with a lower overall survival compared to the low *MAP1LC3B* expressing group ($n = 26$) ($p = 0.039$). Additionally, patients with high *MAP1LC3B* levels had less probability for metastasis-free survival ($p = 0.0095$), shown in Figure 1E. Collectively, these results suggest a possible link between autophagy activation and OS disease outcome.

3.2 | Chemotherapy Induces Autophagy In Vitro

A dose response assay was carried out to determine the IC_{50} for cisplatin or doxorubicin hydrochloride in HOS-143B cells. For cisplatin the IC_{50} value was $5 \mu M$ (Figure 2A). For doxorubicin hydrochloride treatment, $0.75 \mu M$ of the drug was required to reduce the cell population of HOS-143B cells to half (Figure 2B).

HOS-143B cells were treated with the respective IC_{50} dose of chemotherapy for western blotting analysis of autophagy markers. Figure 2C showed an increase in autophagic flux, characterized by the increased conversion of LC3-I to LC3-II. The LC3-II:LC3-I protein levels increased 9.13-fold (p -value: 0.039) with cisplatin treatment and 27.63-fold (p -value: 0.016) with doxorubicin hydrochloride treatment versus the untreated control (Figure 2D). The downregulation of p62 protein levels following chemotherapy confirmed autophagic clearance through the activation of autophagy. A 4.34-fold (p -value: 0.040) and 5.62-fold (p -value: 0.041) reduction in p62 protein levels was observed following cisplatin and doxorubicin hydrochloride treatment, respectively in comparison to the untreated HOS-143B cells (Figure 2E). To further investigate the effects of chemotherapy treatment on autophagy induction, drug-treated HOS-143B cells were probed for LC3 puncta formation to detect changes in autophagic flux. Cells treated with doxorubicin or cisplatin displayed an increase in LC3 puncta formation, which is an index for the number of autophagosomes contained in the cytoplasm. Together, these results confirm that autophagy is activated with chemotherapy in HOS-143B cells (Figure 2F).

3.3 | ATG7 KO Disrupts Autophagy

To further define the fundamental role of autophagy in response to chemotherapeutic agents, *ATG7* expression was stably knocked out (KO) by CRISPR/Cas9 and downstream responses quantified. For gene disruption, gRNA was targeted to *ATG7* gene at Exon 11 of HOS-143B cells (Figure 3Ai). The cleavage efficiency in the pooled HOS-143B cell population following *ATG7* KO was 36% as shown in Figure 3Aii. Single cell clonal isolation was performed to select specific clones with constitutive knockout of *ATG7*. Following clonal selection, *ATG7* gene and protein levels from a single cell clonal isolate showed a significant reduction in *ATG7*^{-/-} compared to wild-type (WT) HOS-143B cells (14.8-fold $p < 0.001$ and 34,429-fold, $p < 0.0001$ respectively; Figure 3B–D). To further explore the effect of *ATG7* KO on autophagy, levels of key biomarkers of autophagy (LC3-II:LC3-I and p62) were analyzed alongside *ATG5*. *ATG7* KO inhibited autophagy in HOS-143B cells as indicated by a significant decrease in LC3-II:LC3-I (2.9-fold, $p = 0.0006$; Figure 3C,E) and an increase in p62 levels (2.7-fold $p < 0.0001$; Figure 3B,F) in comparison to WT HOS-143B cells. *ATG5*-*ATG12* complex formation was inhibited in *ATG7*^{-/-} HOS-143B cells as indicated by the increase in protein levels of unconjugated *ATG5* (63-fold, $p < 0.0001$; Figure 3B,H) coupled with a decrease in conjugated *ATG5*-*ATG12* (913-fold, $p < 0.0001$; Figure 3B,G) in *ATG7*^{-/-} HOS-143B cells compared to WT HOS-143B cells. Additionally, protein levels were also measured in HOS-143B cells administered with Cas9 alongside a non-targeting sgRNA sequence that was used as (NTC). The non-targeting sgRNA does not recognize any sequence in the human genome. The insignificant changes observed between the WT and NTC HOS-143B cells implies that observed effects were specific to the *ATG7* sgRNA and not an off-target effect caused by Cas9 delivery. This confirmed the role of the E1-like enzymatic activity of *ATG7* in the formation of the two conjugates, LC3-II and *ATG5*-*ATG12* that is crucial in the autophagy process.




FIGURE 1) | Legend on next page.

FIGURE 1 | LC3 correlates to OS grade and disease progression. (A) Representative images of immunohistochemical detection of LC3 A/B in primary OS tumor tissue of varying grades and stages and normal cortical bone tissue. (B) Quantification analysis of positive LC3 A/B area coverage (%) based on tumor grade (NB, $n=4$; G2, $n=42$; G3, $n=38$). (C) Quantification analysis of positive LC3 A/B area coverage (%) based on tumor stage (NB, $n=4$; IA, $n=12$; IB, $n=32$; IIA, $n=2$; IIB, $n=32$; IIIB, $n=2$; IVB, $n=2$). (D) Kaplan–Meier curve of *MAP1LC3B* gene expression and overall survival probability between OS patient group (GSE42352) with high (blue, $n=62$) and low (red, $n=26$) expressing *MAP1LC3B* tumors ($p=0.039$). (E) Kaplan–Meier curve of *MAP1LC3B* gene expression and metastasis-free survival probability between OS patient group (GSE42352) with high (blue, $n=62$) and low (red, $n=26$) expressing *MAP1LC3B* tumors ($p=0.0095$). Data is presented as mean $\pm$ SEM. $^{**}p<0.01$. G2, grade 2; G3, grade 3; NB, normal cortical bone.

3.4 | Autophagy Inhibition Enhances Chemosensitivity and Reduces HOS-143B Cell Migration

Levels of autophagy markers suggested that autophagy inhibition mediated by *ATG7* knockout is sustained following chemotherapy in HOS-143B cells characterized by the accumulation of p62 and decreased conversion of LC3-I to LC3-II (Figure 4A). Figure 4B–E demonstrates the dose response curves and graphical representation of the IC_{50} values of DOX or CIS for *ATG7*^{−/−}, NTC and WT HOS-143B cells. The IC_{50} values for CIS in *ATG7*^{−/−} HOS-143B cells are $4.5\mu M \pm 0.21$ and in WT HOS-143B are $7.0\mu M \pm 0.69$ (1.6-fold decrease, $p=0.0036$). These results confirmed that *ATG7* knockout/autophagy inhibition significantly sensitized HOS-143B cells to CIS treatment. The IC_{50} of DOX in *ATG7*^{−/−} and WT HOS-143B cells was 0.7 and 0.6 μM respectively with no statistically significant fold change. Hence, *ATG7* KO and subsequent autophagy inhibition had no effect on the sensitivity of DOX in HOS-143B cells.

The wound healing migration assay revealed no difference in the migratory distance between *ATG7*^{−/−}, NTC, and WT HOS-143B cells under normal conditions. However, treatment with DOX and CIS displayed a 93.2% and 97.2% decrease in migratory distance in the *ATG7*^{−/−} compared to NTC HOS-143B cells, respectively ($p<0.05$; Figure 4F). These results imply that autophagy inhibition reduced the migratory potential of chemotherapy-treated highly aggressive HOS-143B cells.

3.5 | Pharmacological Inhibition of ATR Enhanced CIS Sensitivity

The semi-quantitative phosphorylation levels of 45 different kinases/related proteins associated with various signaling pathways were assessed between autophagy-inhibited (*ATG7*^{−/−} HOS-143B) and NTC HOS-143B cells. The data as shown in Figure 5A,B revealed a decrease in phosphorylation of p53 at S15 in autophagy-inhibited *ATG7*^{−/−} HOS-143B cells compared to NTC HOS-143B cells. This led to the identification of small molecule inhibitors of ATM and ATR kinases that are responsible for the phosphorylation of p53 at S15 called KU-60019 and VE-821 respectively. Figure 5C,D shows the dose response curve and IC_{50} values for DOX with/without of either 1 μM KU-60019 or VE-821. No significant differences were noted. However, a 2.00-fold significant decrease (p -value=0.007) in IC_{50} for CIS was observed with 1 μM VE-821 compared to the control (Figure 5E,F). This implies that a lower dose of CIS is required to reduce the population of HOS-143B cells to half when

combined with ATR inhibitor (ATRi) VE-821. No significant changes in CIS sensitivity were observed with ATM inhibitor (ATMi) KU-60019.

To confirm that the increase in sensitivity to CIS following VE-821/ATRi A (1 μM) treatment is a class effect, three other small molecule ATR inhibitors, namely, BAY1895344/ATRi B (0.1 μM), AZD6738/ATRi C (1 μM), and AZ20/ATRi D (1 μM), were assessed. The concentration of inhibitors was determined following an initial toxicity screen based on negligible effects on cellular growth (0.001–10 μM ; 10-fold dilutions). The IC_{50} values for ATRi A–D were $2.15\mu M \pm 0.45$, $0.63\mu M \pm 0.03$, $0.83\mu M \pm 0.14$, and $0.68\mu M \pm 0.01$, respectively (CIS $IC_{50}=3.10\mu M \pm 0.26$). All investigated ATR inhibitors significantly increased sensitivity to CIS treatment, as shown in Figure 5G,H. The fold changes and p -values are listed in Table 1. Interestingly, 0.01 μM BAY1895344/ATRi B was most efficient at enhancing growth inhibition in CIS-treated HOS-143B cells. Hence, ATRi B was used for further investigation.

3.6 | Pharmacological Inhibition of ATR Enhanced Cellular Apoptosis and Blocked p53 Phosphorylation and Autophagy

Figure 6A–C demonstrates flow cytometry analysis used to determine the percentage of Annexin V-positive and/or PI-positive in HOS-143B cells treated with/without CIS and/or ATRi. CIS treatment induced cell death as indicated by a significant increase in the early/late apoptotic cell population; 5.51% in untreated control versus 67.27% in CIS-treated HOS-143B cells. The combination of ATR inhibitor and CIS-treatment significantly increased the early/late apoptotic cell population further by 23.27% (p -value: 0.003, CIS vs. CIS + ATRi). This suggests that ATR inhibition significantly enhanced CIS-induced apoptosis in HOS-143B cells. The effect of ATR inhibition on phospho-53 (S15) and autophagy levels is shown in Figure 6D–J, respectively. Treatment significantly increased the phosphorylation of p53 in comparison to untreated HOS-143B cells (16.86-fold; p -value: <0.0001). However, treatment with 0.01 μM ATRi significantly reduced the protein levels of total p53 (463-fold; p -value: <0.0001) as well as phospho-p53 (13.32-fold; p -value: <0.0001) compared to HOS-143B cells treated with CIS only. This implies that treatment increased phosphorylation of p53 at S15 and ATR inhibition whilst blocking CIS-treatment blocked the phosphorylation of p53 and reduced total p53 protein levels in HOS-143B cells. The protein levels of ATG7 were significantly reduced following treatment with CIS and ATRi in comparison to CIS treatment alone (p -value: <0.0001). Thus, ATR inhibition depleted ATG7 protein levels in CIS-treated HOS-143B cells.




FIGURE 2 | Activation of autophagy in chemotherapy-treated HOS-143B cells. (A) Dose response curve for cisplatin treatment. (B) Dose response curve for doxorubicin hydrochloride treatment. The HOS-143B cells were dosed with either cisplatin or doxorubicin hydrochloride in increasing concentrations up to 200 or 20 μM , respectively. (C) Western blotting images of LC3-I, LC3-II, p62, and β -actin protein levels in 5 μM cisplatin-treated or 0.75 μM doxorubicin hydrochloride-treated HOS-143B cells. Untreated HOS-143B cells served as the control. β -actin is used as an internal control. Graphical representation of fold changes in protein levels (D) LC3-II:LC3-I and (E) p62 protein levels in cisplatin-treated and doxorubicin hydrochloride-treated HOS-143B cells relative to the control. (F) FITC-LC3 and DAPI immunofluorescence images of HOS-143B cells treated with cisplatin (10 μM) or doxorubicin hydrochloride (1 μM) for 48 h. Data are expressed as mean $\pm$ SD. For all data $n = 3$ cell culture replicates run in triplicate; $*p \leq 0.05$.

Furthermore, a significant decrease in LC3-I, LC3-II and p62 was recorded with ATR inhibition in CIS-treated HOS-143B cells (p -values: <0.0001). Together, this suggests that the autophagy pathway is inhibited via ATR inhibition in CIS-treated HOS-143B cells.

4 | Discussion

Autophagy is an evolutionarily conserved pathway that is used by cells to recycle damaged cellular components as a mechanism of adaptation to adverse environmental stimuli including cancer cell




FIGURE 3 | Legend on next page.

FIGURE 3 | KO of *ATG7* by CRISPR/Cas9 ablates autophagy in HOS-143B cells. (Ai) Schematic illustration of the binding site of TrueGuide sgRNA on Exon 11 of *ATG7* gene. The sgRNA guides the Cas9 endonuclease to the target site for enzymatic double stranded cleavage (ThermoFisher.com). (Aii) Gel electrophoresis of PCR product for the cleavage assay shows a 36% reduction of *ATG7* expression in the pooled cell population following *ATG7* KO. (B) qRT-PCR relative expression of *ATG7* normalized to GAPDH in *ATG7*^{-/-}, NTC and WT HOS-143B cells following single cell clonal isolation for constitutive knockout of *ATG7*. (C) Western blotting images of *ATG7*, LC3-I, LC3-II, p62, *ATG5-ATG12*, *ATG5* and β -actin protein levels in *ATG7*^{-/-}, NTC and WT HOS-143B cells following single cell clonal isolation for constitutive knockout of *ATG7*. Graphical representation of fold changes in relative protein levels of (D) *ATG7*, (E) LC3-II:LC3-I, (F) p62, (G) *ATG5-ATG12*, (H) *ATG5* in *ATG7*^{-/-} and NTC compared to the WT HOS-143B cells. Data are expressed as mean $\pm$ SD. For all data $n = 3$ biological replicates run in triplicate; **** $p < 0.0001$; *** $p < 0.001$; ** $p < 0.01$ (One-way ANOVA).




FIGURE 4 | Chemosensitivity and migration of *ATG7* knockout HOS-143B cells. (A) Western blotting images of LC3-I, LC3-II, p62 and β -actin protein levels in *ATG7*^{-/-}, NTC and WT HOS-143B cells treated with 5 μ M of cisplatin or 0.75 μ M of doxorubicin hydrochloride. Untreated cells served as the control. To assess chemosensitivity, *ATG7*^{-/-}, NTC and WT HOS-143B cells were dosed with DOX and CIS in increasing concentrations up to 200 μ M and 20 μ M, respectively. (B) The dose response curve for DOX treatment. (C) Graphical representation of IC₅₀ of DOX. (D) The dose response curve for CIS treatment. (E) Graphical representation of IC₅₀ of CIS. To assess migration, a scratch assay was carried out and migratory distance was measured after 48 h of incubation. (F) Graphical representation of migratory distance (μ m) of *ATG7*^{-/-}, NTC and WT HOS-143B, in DOX or CIS-treated and untreated conditions. Data are expressed as mean $\pm$ SD. For all data $n = 3$ biological replicates run in triplicate; ** $p < 0.01$; * $p < 0.05$ (One-way ANOVA).




FIGURE 5 | Legend on next page.

FIGURE 5 | Chemosensitivity of HOS-143B cells following co-administration with ATMi/ATRi. (A) Image showing the relative levels of phospho-p53 (S15; boxed) in *ATG7*^{-/-} and NTC HOS-143B cells. (B) Graphical representation of relative phosphorylation of p53 (S15). For the dose response assay, HOS-143B cells were dosed with CIS or DOX in increasing concentrations up to 200 μ M or 10 μ M respectively alongside 1 μ M of either ATMi/KU-60019 or ATRi/VE-821. (C) Dose response curve for DOX with/without 1 μ M ATMi/ATRi. (D) Graphical representation of IC₅₀ of DOX with/without 1 μ M ATMi/ATRi. (E) Dose response curve for CIS with/without 1 μ M ATMi/ATRi. (F) Graphical representation of IC₅₀ values of CIS with/without 1 μ M ATMi/ATRi. (G) Dose response curve of CIS combined with/without ATRi A–D. (H) Graphical representation of IC₅₀ values of CIS with/without ATRi A–D. VE-821/ATRi A, BAY1895344/ATRi B, AZD6738/ATRi C and AZ20/ATRi D. 1 μ M of ATRi A, ATRi C and ATRi D and 0.1 μ M of ATRi B. Data are expressed as mean $\pm$ SD. For all data $n = 3$ biological replicates run in triplicate; ** $p < 0.01$; * $p < 0.05$ (two-sample *t*-test vs. control).

TABLE 1 | IC₅₀ fold changes and *p*-values of CIS following ATR inhibition in HOS-143B cells. For all data $n = 3$ biological replicates run in triplicates (two-sample *t*-test vs. control).

Inhibitor	Fold change	<i>p</i>
VE-821/ATRi A	−1.44	0.050
BAY1895344/ATRi B	−4.89	0.008
AZD6738/ATRi C	−3.72	0.003
AZ20/ATRi D	−4.58	0.004

replication stress as well as exposure to chemotherapeutic agents. This study showed that higher autophagy levels are associated with lower metastasis-free survival as well as overall survival in OS patients. Moreover, in vitro studies showed higher autophagy levels in OS cells treated with chemotherapy, and blocking autophagy through the KO of *ATG7* increased cisplatin sensitivity and reduced OS cell migration. Further, p15 phosphorylation on S15 was shown to be reduced in the autophagy inhibited model of HOS-143B OS cells, and blocking this phosphorylation activity via small molecule inhibitors mimicked the *ATG7* KO effect in HOS-143B cells, increasing sensitivity to cisplatin.

In the current study, it was evident through the staining of LC3 that higher autophagy levels were present in advanced OS tumors. Furthermore, high *MAP1LC3B* gene expression was associated with poorer survival outcomes and increased metastasis in OS patients. These results agree with a study carried out by White *et al.* [23], who have shown that higher levels of autophagy proteins were measured in high-grade glioma in comparison to low-grade tissues.

Several studies have shown that chemotherapy can upregulate autophagy in tumors as a means to protect transformed cells from organelle damage and nutrient deprivation [12, 24, 25]. In the current study, analysis of DOX - CIS-treated HOS-143B cells suggested that autophagy is activated as a cellular coping mechanism following DNA damage induced by chemotherapy. Therefore, targeting autophagy could be a therapeutic strategy that may improve the efficacy of the standard of care anti-cancer treatment. *ATG7*, being an E1 ligase, plays a crucial role in autophagy regulation and it has been reported that *ATG7*-dependent autophagy modulates the progression of several types of cancer [26–28]. In this study, a significant increase in conversion of LC3-I to lipidated LC3-II and increased clearance of p62 was observed in CRISPR/Cas9 *ATG7*^{-/-} cells in comparison to WT and NTC HOS-143B cells.

This data agrees with the observations made in *ATG7* knockout mutants by Cui *et al.* [29], which showed high p62 protein levels and lower levels of LC3-II proteins in the *ATG7* knockout mutants compared to the controls (WT and empty vector control) suggesting that *ATG7* knockout efficiently impeded autophagy. In addition to the role of the *ATG7* enzymatic activity in the formation of the LC3-I-PE conjugate, it is also involved in the formation of the *ATG5*-*ATG12* conjugate. In the current study, the *ATG5*-*ATG12* conjugate was not formed in *ATG7*^{-/-} HOS-143B cells and *ATG5* was present in its free form, confirming ablation of the autophagy process.

To gain a mechanistic insight into the consequences of autophagy inhibition on chemosensitivity of OS, a chemotherapy dose response assay showed that CIS sensitivity increased in *ATG7*^{-/-} HOS-143B cells, characterized by a reduction in the IC₅₀ value. These findings agree with a study conducted by Piya *et al.* [30] who showed that suppression of *ATG7* in acute myeloid leukemia enhanced the sensitivity to chemotherapeutic agents marked by an increase in DNA damage and cellular apoptosis. CIS induces DNA damage, and preventing the repair of damaged DNA through autophagy inhibition leads to increased cell death [31]. On the other hand, DOX induces cell death through multiple pathways, and autophagy inhibition does not affect these pathways significantly, as shown in the current study [32, 33].

Several different kinases as well as phosphatases are responsible for regulating autophagy through phosphorylation activity [34]. In the current study, variations in phosphorylation levels of p53 (S15) were revealed in *ATG7*^{-/-} HOS-143B cells in comparison to NTC HOS-143B cells. The phosphorylation of p53 at S15 serves as a critical trigger for the DDR in response to DNA damage inducing agents. ATM and ATR are two protein kinases involved in the phosphorylation of p53 at S15, recognizing double-strand DNA breaks and replication stress, respectively [35, 36].

Currently, pharmacological inhibitors of ATM and ATR are in preclinical and clinical trials. The data obtained from pre-clinical studies have shown promising results for their use in combination with standard of care treatments, paving the way for clinical testing [37]. This study utilized two small molecule inhibitors for specific inhibition of ATM and ATR kinase activity. The dose response analysis revealed a statistically significant increase in sensitivity to CIS in HOS-143B cells treated with ATR but not ATM inhibitors. As CIS-induced DNA damage primarily activates ATR and not ATM, it explains these findings and suggests that ATR inhibition dictates




FIGURE 6 | Legend on next page.

FIGURE 6 | Pharmacological inhibition of ATR enhanced apoptosis and blocked p53 phosphorylation and autophagy. (A) Annexin V/PI staining of HOS-143B cells with/without 5 μ M CIS and/or 0.01 μ M ATRi, BAY-1895344. Quadrant guide: Lower left = live cells; Lower right, early apoptosis; Upper left, necrosis; Upper right, late apoptosis. (B) Percentage of the live, early and late apoptotic and necrotic cell population. (C) Statistical analysis of live, early and late apoptotic and necrotic cell population. (D) Western blotting images of total p53, phospho-p53 and β -actin protein levels in HOS-143B cells treated with either 5 μ M CIS or 0.01 μ M ATRi, or a combination of both. Untreated cells served as the control. Graphical representation of fold changes in protein levels of (E) Total p53 and (F) phospho-p53 relative to the control. (G) Western blotting images of ATG7, LC3-I, LC3-II, and β -actin protein levels in HOS-143B cells treated with either 5 μ M CIS or 0.01 μ M ATRi, or a combination of both. Untreated cells served as the control. Graphical representation of fold changes in protein levels of (H) ATG7 (I) LC3-II:LC3-I, and (J) p62 relative to the control. Data are expressed as mean $\pm$ SD. For all data $n=3$ biological replicates run in triplicate; **** $p<0.0001$; *** $p<0.001$; ** $p<0.01$; * $p\leq 0.05$ (flow cytometry: One-way ANOVA; Western blot: two-sample t -test vs. control).




FIGURE 7 | ATRi blocked phosphorylation of p53 (S15) and enhanced cell death in CIS-treated OS cells.

drug synergy for CIS treatment in OS [38]. Furthermore, in the current study Western Blotting analysis confirmed a decrease in phospho-p53 following ATR inhibition with BAY-1895344 in CIS-treated HOS-143B cells. This suggests that ATR is one of the central kinases involved in the phosphorylation of p53 at serine 15 and its inhibition can independently decrease the phospho-p53 (S15) levels [37]. Furthermore, Western Blotting analysis revealed a decrease in ATG7 protein levels in BAY-1895344 and CIS-treated HOS-143B cells. This suggests a possible association between phospho-p53-mediated DDR and ATG7/autophagy in OS chemoresistance. A study by Lee *et al.* [39], showed that ATG7 and p53 bind to each other directly and as such, not only does p53 regulate autophagy but ATG7 can regulate p53. However, this needs to be investigated in the context of OS chemoresistance. Interestingly however, the addition of BAY-1895344 and CIS resulted in a down-regulation in p62 levels. During autophagy, p62 is degraded and serves as a marker of autophagic flux. However, it has been shown that VX-970 increases p62 through an ATR-independent mechanism, as this effect was seen only with VX-970 and the precursor another ATR inhibitor VE-821 but not with other ATR inhibitors such as BAY-1895344 [40]. This suggests off-target activity linked to their shared structure, with inhibitor assays further suggesting that VX-970 disrupts late-stage autophagy.

Flow cytometry analysis of Annexin V/PI-stained HOS-143B cells showed that although CIS treatment caused apoptotic cell death, combining an ATR inhibitor alongside CIS treatment significantly increased the incidence of apoptosis. This suggests that ATRi may potentiate the effects of CIS treatment through reversal of the phospho-p53-mediated DDR and autophagy in HOS-143B OS cells (Figure 7). ATR inhibitors have a significant impact on cells active within the cell cycle, such as cancer cells, leading to a sharp increase in the number of apoptotic cells. However, this treatment is ineffective, let alone beneficial for the survival of noncycling cells, such as healthy normal cells [41]. A proof-of-principle study shows that ATR inhibition in pancreatic ductal adenocarcinoma xenografts increased sensitivity to

radiation as well as gemcitabine treatment without exerting cytotoxicity to normal cells [42].

BAY-1895344 is an orally administered ATR inhibitor by Bayer AG (Germany) that entered clinical trials for the treatment of lymphomas and solid cancers in 2017. Currently, [ClinicalTrials.gov](https://clinicaltrials.gov) shows planned clinical trials investigating the safety and efficacy of BAY-1895344 for treatment of several other cancers, such as advanced pancreatic and ovarian cancer [38, 43]. ATR inhibitors show promise as adjuvant therapies in OS, but several challenges must be addressed for clinical translation. These include potential toxicity to normal proliferating cells, OS tumor heterogeneity, and compensatory resistance mechanisms such as ATM or CHK1 activation.

The current study has shown that autophagy may play a role in determining the fate of OS patients, as higher levels of autophagy are detected in advanced OS tumors and are also found to be associated with poorer survival and metastasis. Chemotherapy increases autophagy levels, restoring cellular homeostasis that allows for OS tumor progression. The inhibition of autophagy by ATG7 KO as well as the inhibition of phospho-p53 (S15) via inhibitors of ATR protein kinase enhanced CIS sensitivity in OS. These findings could ultimately lead to novel adjuvant therapy for OS, lowering the dosage of CIS required by combining it with an ATR kinase inhibitor. This could reduce the harsh side effects of CIS treatment as well as overcome chemoresistance and tumor recurrence, potentially improving the overall survival of OS patients.

Author Contributions

Janice S. Pereira: data curation (equal), formal analysis (equal), investigation (lead), methodology (equal), project administration (equal), validation (equal), writing – original draft (lead), writing – review and editing (equal). **Gabriel Rosa:** data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), writing – original draft (equal), writing – review and editing (equal). **Aine Pears:** data curation (equal), formal analysis (equal), investigation (equal), writing – original draft (equal), writing – review and editing (equal). **Beata**

Burczynska: formal analysis (equal), investigation (equal), methodology (equal), software (equal), supervision (equal), writing – original draft (equal), writing – review and editing (equal). **Britta Stordal:** data curation (equal), formal analysis (equal), funding acquisition (equal), investigation (equal), methodology (equal), supervision (equal), writing – original draft (equal), writing – review and editing (equal). **Scott J. Roberts:** conceptualization (lead), data curation (supporting), formal analysis (supporting), investigation (lead), methodology (lead), supervision (supporting), writing – original draft (supporting), writing – review and editing (supporting). **Helen C. Roberts:** conceptualization (lead), data curation (supporting), formal analysis (supporting), funding acquisition (lead), investigation (lead), methodology (lead), project administration (lead), resources (lead), supervision (lead), validation (lead), writing – original draft (supporting), writing – review and editing (supporting).

Acknowledgements

This study was supported by the Bone Cancer Research Trust, UK. We thank Catarina Sofia Bento Caetano for assistance with our experiments.

Funding

This research was part-funded by the Bone Cancer Research Trust.

Ethics Statement

This research was approved by the Middlesex University Natural Sciences Research Ethics Committee (Reference 7653).

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data available on request from the authors.

References

1. A. Misaghi, A. Goldin, M. Awad, and A. A. Kulidjian, "Osteosarcoma: A Comprehensive Review," *SICOT-J* 4 (2018): 12.
2. P. Picci, "Osteosarcoma (*Osteogenic sarcoma*)," *Orphanet Journal of Rare Diseases* 2 (2007): 6, <https://doi.org/10.1186/1750-1172-2-6>.
3. M. S. Isakoff, S. S. Bielack, P. Meltzer, and R. Gorlick, "Osteosarcoma: Current Treatment and a Collaborative Pathway to Success," *Journal of Clinical Oncology* 33 (2015): 3029–3035.
4. J. Gill, M. K. Ahluwalia, D. Geller, and R. Gorlick, "New Targets and Approaches in Osteosarcoma," *Pharmacology & Therapeutics* 137 (2013): 89–99, <https://doi.org/10.1016/j.pharmthera.2012.09.003>.
5. S. Li, W. Sun, H. Wang, D. Zuo, Y. Hua, and Z. Cai, "Research Progress on the Multidrug Resistance Mechanisms of Osteosarcoma Chemotherapy and Reversal," *Tumor Biology* 36 (2015): 1329–1338.
6. S. M. Botter, D. Neri, and B. Fuchs, "Recent Advances in Osteosarcoma," *Current Opinion in Pharmacology* 16 (2014): 15–23, <https://doi.org/10.1016/j.coph.2014.02.002>.
7. A. Luetke, P. A. Meyers, I. Lewis, and H. Juergens, "Osteosarcoma Treatment—Where Do We Stand? A State of the Art Review," *Cancer Treatment Reviews* 40, no. 4 (2013): 523–532, <https://doi.org/10.1016/j.ctrv.2013.11.006>.
8. L. Marchandet, M. Lallier, C. Charrier, M. Baud'huin, B. Ory, and F. Lamoureux, "Mechanisms of Resistance to Conventional Therapies for Osteosarcoma," *Cancers (Basel)* 13 (2021): 683.

9. I. Lilienthal and N. Herold, "Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies," *International Journal of Molecular Sciences* 21 (2020): 1–56.
10. Y. Zhou, K. Sun, Y. Ma, et al., "Autophagy Inhibits Chemotherapy-Induced Apoptosis Through Downregulating Bad and Bim in Hepatocellular Carcinoma Cells," *Scientific Reports* 4 (2014): 1–9.
11. L. Mele, V. del Vecchio, D. Liccardo, et al., "The Role of Autophagy in Resistance to Targeted Therapies," *Cancer Treatment Reviews* 88 (2020): 102043.
12. X. Sui, R. Chen, Z. Wang, et al., "Autophagy and Chemotherapy Resistance: A Promising Therapeutic Target for Cancer Treatment," *Cell Death & Disease* 4 (2013): e838, <https://doi.org/10.1038/cddis.2013.350>.
13. S. Chen, S. K. Rehman, W. Zhang, A. Wen, L. Yao, and J. Zhang, "Autophagy Is a Therapeutic Target in Anticancer Drug Resistance," *Biochimica et Biophysica Acta* 1806 (2010): 220–229.
14. E. White, "Deconvoluting the Context-Dependent Role for Autophagy in Cancer," *Nature Reviews Cancer* 12, no. 6 (2012): 401–410.
15. X. Li, Y. Zhou, Y. Li, et al., "Autophagy: A Novel Mechanism of Chemoresistance in Cancers," *Biomedicine and Pharmacotherapy* 119 (2019): 109415.
16. S. Desai, Z. Liu, J. Yao, et al., "Heat Shock Factor 1 (HSF1) Controls Chemoresistance and Autophagy Through Transcriptional Regulation of Autophagy-Related Protein 7 (ATG7)," *Journal of Biological Chemistry* 288 (2013): 9165–9176.
17. K. Zhu, K. Dunner, and D. J. McConkey, "Proteasome Inhibitors Activate Autophagy as a Cytoprotective Response in Human Prostate Cancer Cells," *Oncogene* 29 (2010): 451–462.
18. W. Han, H. Pan, Y. Chen, et al., "EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells," *PLoS One* 6 (2011): e18691.
19. S. Suffixidharan, K. Jain, and A. Basu, "Regulation of Autophagy by Kinases," *Cancers (Basel)* 3 (2011): 2630–2654.
20. W. Feng, T. Wu, X. Dan, et al., "Phosphorylation of Atg31 Is Required for Autophagy," *Protein & Cell* 6 (2015): 288–296.
21. S. J. Cherra, S. M. Kulich, G. Uechi, et al., "Regulation of the Autophagy Protein LC3 by Phosphorylation," *Journal of Cell Biology* 190 (2010): 533–539.
22. C. R. Justus, N. Leffler, M. Ruiz-Echevarria, and L. V. Yang, "In Vitro Cell Migration and Invasion Assays," *Journal of Visualized Experiments* 88 (2014): e51046, <https://doi.org/10.3791/51046>.
23. E. J. White, V. Martin, J. L. Liu, et al., "Autophagy Regulation in Cancer Development and Therapy," *American Journal of Cancer Research* 1 (2011): 362–372.
24. R. C. Russell, H. X. Yuan, and K. L. Guan, "Autophagy Regulation by Nutrient Signaling," *Cell Research* 24 (2014): 42–57.
25. Y. L. Hu, M. DeLay, A. Jahangiri, et al., "Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma," *Cancer Research* 72 (2012): 1773–1783.
26. Y. Gonzalez, B. Aryal, L. Chehab, and V. A. Rao, "Atg7- and Keap1-Dependent Autophagy Protects Breast Cancer Cell Lines Against Mitoquinone-Induced Oxidative Stress," *Oncotarget* 5 (2014): 1526–1537.
27. J. Hu, L. Zhang, Z. Mei, et al., "Interaction of E3 Ubiquitin Ligase MARCH7 With Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer," *Cellular Physiology and Biochemistry* 47 (2018): 654–666.

28. J. Mandelbaum, N. Rollins, P. Shah, et al., "Identification of a Lung Cancer Cell Line Deficient in atg7-Dependent Autophagy," *Autophagy* 19 (2015), <https://doi.org/10.1080/15548627.2015.1056966>.
29. J. Cui, S. J. L. Chew, Y. Shi, Z. Gong, and H. M. Shen, "CRISPR System for Genome Engineering: The Application for Autophagy Study," *BMB Reports* 50 (2017): 247–256.
30. S. Piya, S. M. Kornblau, V. R. Ruvalo, et al., "Atg7 Suppression Enhances Chemotherapeutic Agent Sensitivity and Overcomes Stroma-Mediated Chemoresistance in Acute Myeloid Leukemia," *Blood* 128 (2016): 1260–1269.
31. L. Galluzzi, L. Senovilla, I. Vitale, et al., "Molecular Mechanisms of Cisplatin Resistance," *Oncogene* 31 (2012): 1869–1883.
32. C. Chen, L. Lu, S. Yan, et al., "Autophagy and Doxorubicin Resistance in Cancer," *Anti-Cancer Drugs* 29 (2018): 1–9.
33. J. Fellenberg, M. J. Dechant, V. Ewerbeck, and H. Mau, "Identification of Drug-Regulated Genes in Osteosarcoma Cells," *International Journal of Cancer* 105 (2003): 636–643.
34. D. G. McEwan and I. Dikic, "The Three Musketeers of Autophagy: Phosphorylation, Ubiquitylation and Acetylation," *Trends in Cell Biology* 21 (2011): 195–201.
35. R. Prevo, E. Fokas, P. M. Reaper, et al., "The Novel ATR Inhibitor VE-821 Increases Sensitivity of Pancreatic Cancer Cells to Radiation and Chemotherapy," *Cancer Biology & Therapy* 13 (2012): 1072–1081.
36. J. Loughery, M. Cox, L. M. Smith, and D. W. Meek, "Critical Role for p53-Serine 15 Phosphorylation in Stimulating Transactivation at p53-Responsive Promoters," *Nucleic Acids Research* 42 (2014): 7666–7680.
37. A. M. Weber and A. J. Ryan, "ATM and ATR as Therapeutic Targets in Cancer," *Pharmacology & Therapeutics* 149 (2015): 124–138.
38. F. M. Barnieh, P. M. Loadman, and R. A. Falconer, "Progress Towards a Clinically-Successful ATR Inhibitor for Cancer Therapy," *Current Research in Pharmacology and Drug Discovery* 2 (2021): 100017.
39. I. H. Lee, Y. Kawai, M. M. Fergusson, et al., "Atg7 Modulates p53 Activity to Regulate Cell Cycle and Survival During Metabolic Stress," *Science* (1979) 337 (2012): 911.
40. E. Bowler, A. Skwarska, J. D. Wilson, et al., "Pharmacological Inhibition of ATR Can Block Autophagy Through an ATR-Independent Mechanism," *iScience* 23 (2020): 101668.
41. X. Liang, Q. Yang, W. Wang, T. Liu, and J. Hu, "Ve-822 Mediated Inhibition of ATR Signaling Sensitizes Chondrosarcoma to Cisplatin via Reversion of the DNA Damage Response," *Oncotargets and Therapy* 12 (2019): 6083–6092.
42. E. Fokas, R. Prevo, J. R. Pollard, et al., "Targeting ATR In Vivo Using the Novel Inhibitor VE-822 Results in Selective Sensitization of Pancreatic Tumors to Radiation," *Cell Death & Disease* 3 (2012): e441.
43. L. Mei, J. Zhang, K. He, and J. Zhang, "Ataxia Telangiectasia and Rad3-Related Inhibitors and Cancer Therapy: Where We Stand," *Journal of Hematology & Oncology* 12 (2019): 1–8.